Hashimoto H, Daimaru Y, Enjoji M, Nakagawara A
Second Department of Pathology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
J Clin Pathol. 1989 Jan;42(1):52-5. doi: 10.1136/jcp.42.1.52.
The presence and distribution of N-myc gene product were studied in 13 neuroblastomas and five ganglioneuroblastomas, using immunohistochemical techniques. Nine tumors (eight neuroblastomas and one ganglioneuroblastoma of composite type) contained neuroblastoma cells with positive nuclei for N-myc protein. Microscopic examination showed that most of the positive neuroblastoma cells seemed to be immature, with no apparent neuronal differentiation. Nine of 11 tumours with amplified N-myc gene copies exhibited tumour cells with positive immunostaining for the N-myc gene product, while none of the seven non-N-myc amplified cases contained immunoreactive tumour cells. The survival of the patients positive for N-myc protein was significantly low compared with that of the negative ones. It is concluded that immunohistochemical staining for the N-myc gene product will facilitate prediction of the prognosis of patients with neuroblastoma.
采用免疫组织化学技术，对13例神经母细胞瘤和5例神经节神经母细胞瘤中N-myc基因产物的存在及分布进行了研究。9例肿瘤（8例神经母细胞瘤和1例复合型神经节神经母细胞瘤）含有N-myc蛋白细胞核呈阳性的神经母细胞瘤细胞。显微镜检查显示，大多数阳性神经母细胞瘤细胞似乎不成熟，无明显神经元分化。11例N-myc基因拷贝扩增的肿瘤中有9例显示肿瘤细胞对N-myc基因产物免疫染色呈阳性，而7例未扩增N-myc的病例均未含有免疫反应性肿瘤细胞。与N-myc蛋白阴性的患者相比，N-myc蛋白阳性患者的生存率显著较低。结论是，对N-myc基因产物进行免疫组织化学染色将有助于预测神经母细胞瘤患者的预后。
